- About Us
- Clinical Trials
- News & Publications
- Business Development
A Phase I/Ib clinical trial investigating the safety, pharmacokinetic and pharmacodynamic of SO-C101 as monotherapy and in combination with an anti-PD1 at sites in France (Institut Gustave Roussy), Spain (Vall d’Hebron Institute of Oncology) and the USA (Yale Cancer Center and MD Anderson Cancer Center ). Enrollment of patients started in summer 2019. Cytune Pharma is responsible for the clinical development of SO-C101; SOTIO is the sponsor of the SC103 clinical trial.
SC103 (Eudra CT: 2018-004334-15): A multicenter open-label Phase I/Ib study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in selected patients with advanced/metastatic solid tumors.